File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Plasma concentration of urotensin II is raised in hypertension

TitlePlasma concentration of urotensin II is raised in hypertension
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2004
PublisherLippincott Williams & Wilkins, Ltd. The Journal's web site is located at http://www.jhypertension.com/
Citation
Journal Of Hypertension, 2004, v. 22 n. 7, p. 1341-1344 How to Cite?
AbstractObjectives: Urotensin II is the most potent vasoconstrictor known. Its role in hypertension has not been investigated. Here, we studied the plasma levels in hypertensive and normotensive human subjects. Design: A cross-sectional case-control study. Setting: Hypertension clinic and research clinic of a university teaching hospital. Participants: Sixty-two hypertensive outpatient subjects (52% male, aged 57 ± 13 years) and 62 normotensive controls (45% male, aged 54 ± 13 years) recruited from the general population. Main outcome measures: Plasma urotensin II levels measured by radioimmunoassay, systolic and diastolic blood pressure. Results: Plasma urotensin II was 8.8 ± 0.9 pmol/l in normotensive controls and 13.6 ± 1.4 pmol/l in hypertensive subjects (P = 0.005). In multiple regression analysis, systolic blood pressure was related to plasma urotensin II (β = 0.31, P < 0.001) and age (β = 0.28, P = 0.001), accounting for 10 and 8%, respectively, of the variance in systolic blood pressure. There was no significant correlation with gender, renal function or diabetes. Conclusions: Plasma urotensin II was raised in hypertensive patients compared to normotensive controls, and was directly related to systolic blood pressure. Our findings raise the possibility that urotensin II may have an aetiological role in hypertension and its complications. © 2004 Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/91585
ISSN
2015 Impact Factor: 5.062
2015 SCImago Journal Rankings: 2.193
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorLeung, Ren_HK
dc.contributor.authorMan, YBen_HK
dc.contributor.authorWong, LYFen_HK
dc.date.accessioned2010-09-17T10:21:46Z-
dc.date.available2010-09-17T10:21:46Z-
dc.date.issued2004en_HK
dc.identifier.citationJournal Of Hypertension, 2004, v. 22 n. 7, p. 1341-1344en_HK
dc.identifier.issn0263-6352en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91585-
dc.description.abstractObjectives: Urotensin II is the most potent vasoconstrictor known. Its role in hypertension has not been investigated. Here, we studied the plasma levels in hypertensive and normotensive human subjects. Design: A cross-sectional case-control study. Setting: Hypertension clinic and research clinic of a university teaching hospital. Participants: Sixty-two hypertensive outpatient subjects (52% male, aged 57 ± 13 years) and 62 normotensive controls (45% male, aged 54 ± 13 years) recruited from the general population. Main outcome measures: Plasma urotensin II levels measured by radioimmunoassay, systolic and diastolic blood pressure. Results: Plasma urotensin II was 8.8 ± 0.9 pmol/l in normotensive controls and 13.6 ± 1.4 pmol/l in hypertensive subjects (P = 0.005). In multiple regression analysis, systolic blood pressure was related to plasma urotensin II (β = 0.31, P < 0.001) and age (β = 0.28, P = 0.001), accounting for 10 and 8%, respectively, of the variance in systolic blood pressure. There was no significant correlation with gender, renal function or diabetes. Conclusions: Plasma urotensin II was raised in hypertensive patients compared to normotensive controls, and was directly related to systolic blood pressure. Our findings raise the possibility that urotensin II may have an aetiological role in hypertension and its complications. © 2004 Lippincott Williams & Wilkins.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins, Ltd. The Journal's web site is located at http://www.jhypertension.com/en_HK
dc.relation.ispartofJournal of Hypertensionen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntihypertensive Agents - therapeutic useen_HK
dc.subject.meshBlood Pressureen_HK
dc.subject.meshCase-Control Studiesen_HK
dc.subject.meshCross-Sectional Studiesen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypertension - blood - drug therapy - etiologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshUrotensins - blooden_HK
dc.titlePlasma concentration of urotensin II is raised in hypertensionen_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.hjh.0000125452.28861.f1en_HK
dc.identifier.pmid15201550-
dc.identifier.scopuseid_2-s2.0-3042713965en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-3042713965&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume22en_HK
dc.identifier.issue7en_HK
dc.identifier.spage1341en_HK
dc.identifier.epage1344en_HK
dc.identifier.isiWOS:000222408100016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridLeung, R=7101876102en_HK
dc.identifier.scopusauthoridMan, YB=10245005900en_HK
dc.identifier.scopusauthoridWong, LYF=24476809800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats